206 related articles for article (PubMed ID: 31768815)
1. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
Masuda C; Sugimoto M; Wakita D; Monnai M; Ishimaru C; Nakamura R; Kinoshita M; Yorozu K; Kurasawa M; Kondoh O; Yamamoto K
Clin Exp Metastasis; 2020 Feb; 37(1):199-207. PubMed ID: 31768815
[TBL] [Abstract][Full Text] [Related]
2. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8
Masuda C; Morinaga M; Wakita D; Yorozu K; Kurasawa M; Sugimoto M; Kondoh O
Clin Exp Metastasis; 2022 Apr; 39(2):335-344. PubMed ID: 34797455
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma.
Ilhan-Mutlu A; Osswald M; Liao Y; Gömmel M; Reck M; Miles D; Mariani P; Gianni L; Lutiger B; Nendel V; Srock S; Perez-Moreno P; Thorsen F; von Baumgarten L; Preusser M; Wick W; Winkler F
Mol Cancer Ther; 2016 Apr; 15(4):702-10. PubMed ID: 26809491
[TBL] [Abstract][Full Text] [Related]
6. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
8. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
Ishikura N; Yanagisawa M; Noguchi-Sasaki M; Iwai T; Yorozu K; Kurasawa M; Sugimoto M; Yamamoto K
Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
Wakelee H
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S113-8. PubMed ID: 18520292
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer.
Fu Y; Hu J; Du N; Jiao S; Li F; Li X; Ma J; Zhao H; Kang H
J Chemother; 2016 Jun; 28(3):218-24. PubMed ID: 26038980
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
12. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
13. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
Morgensztern D; Govindan R
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S57-61. PubMed ID: 21885000
[TBL] [Abstract][Full Text] [Related]
15. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in non-small cell lung cancer.
Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases.
Ascha MS; Wang JF; Kumthekar P; Sloan AE; Kruchko C; Barnholtz-Sloan JS
Sci Rep; 2019 Nov; 9(1):17792. PubMed ID: 31780762
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.
Zustovich F; Ferro A; Lombardi G; Farina P; Zagonel V
Chemotherapy; 2014; 60(5-6):294-9. PubMed ID: 25999127
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
20. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
Dowlati A
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
